Document Detail


Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
MedLine Citation:
PMID:  22031258     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Clomiphene citrate (CC) is the most commonly used oral agent for the induction of ovulation. It is a nonsteroidal selective estrogen receptor modulator that has predominant antiestrogenic action resulting in long-lasting estrogen receptor depletion. Side effects include antiestrogenic effects systemically and on the endometrium and cervical mucous. Letrozole is a potent, nonsteroidal, aromatase inhibitor, originally used for postmenopausal breast cancer therapy, at present its only registered indication. We hypothesized that letrozole could mimic the action of CC without depletion of estrogen receptors. As there is no estrogen receptor antagonism, antiestrogenic effects such as poor cervical mucus and thin endometrium are not expected with aromatase inhibitor treatment. In addition, because estrogen receptors in the brain are not depleted, normal negative feedback occurs with letrozole and generally results in monoovulation. We and others have demonstrated the success of aromatase inhibition in inducing ovulation in women with polycystic ovarian syndrome. Letrozole may be very effective for ovulation induction and pregnancy in cases of CC resistance. When used together with follicle-stimulating hormone (FSH) injections, letrozole resulted in a significant reduction in the FSH dose needed for controlled ovarian hyperstimulation. Aromatase inhibitors likely increase ovarian sensitivity to FSH, and may be useful in poor responders and in women undergoing ovarian stimulation for in vitro fertilization. The safety of letrozole in pregnancy outcome studies has been demonstrated by examination of spontaneous pregnancy loss, multiple pregnancy rates, and congenital anomalies compared with a control group of infertility patients treated with CC. In addition, new data suggest that CC may result in cardiac anomalies and other birth defects and in low birth weight babies. We believe aromatase inhibitors are acceptable alternatives to CC as first line oral agents for ovulation induction or controlled ovarian stimulation.
Authors:
Robert F Casper; Mohamed F M Mitwally
Related Documents :
18238988 - Acog practice bulletin: clinical management guidelines for obstetrician-gynecologists n...
14703588 - Antibiotics and other anti-infective agents in pregnancy and lactation.
17334338 - Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during ...
16643598 - Population-based case-control study of oxoline acid use during pregnancy for birth outc...
24041008 - Maternal influenza-like illness, medication use during pregnancy and risk of congenital...
16863798 - Spontaneous dissection of an anomalous systemic artery in the lung during pregnancy: a ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical obstetrics and gynecology     Volume:  54     ISSN:  1532-5520     ISO Abbreviation:  Clin Obstet Gynecol     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0070014     Medline TA:  Clin Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  685-95     Citation Subset:  IM    
Affiliation:
*Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Toronto †Samuel Lunenfeld Research Institute, Mount Sinai Hospital ‡Toronto Centre for Advanced Reproductive Technology, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polycystic ovary syndrome: current infertility management.
Next Document:  Clinical management of the uterine factor in infertility.